Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes

European Journal of Pharmacology

Volumn 395, Issue 3, 2000, Pages 255-263

  Tsubouchi, Yasunori ^a   Sano, Hajime ^a   Yamada, Ryoji ^a   Hashiramoto, Akira ^a   Kohno, Masataka ^a   Kusaka, Yoshiaki ^a   Kondo, Motoharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cyclooxygenase 2; Cyclooxygenase 1; Meloxicam; Rheumatoid arthritis; Synoviocyte

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXAMETHASONE; INDOMETACIN; INTERLEUKIN 1BETA; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DEXAMETHASONE; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDOMETHACIN; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; THIAZINES; THIAZOLES;

EID: 0034600282     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00163-1     Document Type: Article

References (58)

1. Akarasereenont P., Mitchell J.A., Bakhle Y.S., Thiemermann C., Vane J.R. Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages. Eur. J. Pharmacol. 273:1995;121-128.
2. Anderson G.D., Hauser S.D., McGarity K.L., Bremer M.E., Isakson P.C., Gregory S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 97:1996;2672-2679.
3. 2 and cyclooxygenase-2. Eur. J. Biochem. 226:1994;125-131.
4. Appleton I., Tomlinson A., Willoughby D.A. Inducible cyclooxygenase (COX-2): a safer therapeutic target? Br. J. Rheumatol. 33:1994;410-412.
5. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., Medsger T.A., Michell D.M., Neustadt D.H., Pinals R.S., Schaller J.G., Sharp J.T., Wilder R.L., Hunder G.G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
6. Baum C., Kennedy D.L., Forbes M.B. Utilization of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 28:1985;686-692.
7. Blanco F.J., Guitian R., Moreno J., Toro F.J., Galdo F. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J. Rheumatol. 26:1999;1366-1373.
8. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflammaion Res. 45:1996;68-74.
9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
10. Churchill L., Graham A.G., Shih C.K., Pauletti D., Farina P.R., Grob P.M. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology. 4:1996;125-135.
11. Crofford L.J., Wilder R.L., Ristimaki A.P., Sano H., Remmers E.F., Epps H.R., Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J. Clin. Invest. 93:1994;1095-1101.
12. Cromlish W.A., Kennedy B.P. Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays. Biochem. Pharmacol. 52:1996;1777-1785.
13. Dayer J.M., Krane S.M., Russell R.G.G., Robinson D.R. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc. Natl. Acad. Sci. U. S. A. 73:1976;945-949.
14. Engelhardt G., Homma D., Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflammation Res. 44:1995;548-555.
15. Fenn G.C., Morant S.V. Safety of meloxicam: a global analysis of clinical trials. Br. J. Rheumatol. 35(Suppl. 1):1996;68-77.
16. Fiebich B.L., Lieb K., Hull M., Berger M., Bauer J. Effects of NSAIDs on IL-1 β-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. NeuroReport. 7:1996;1209-1213.
17. 2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 265:1990;16737-16740.
18. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann. Intern. Med. 115:1991;787-796.
19. Goldman A.P., Williams C.S., Sheng H., Lamps L.W., Williams V.P., Pairet M., Morrow J.D., DuBois R.N. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis. 19:1998;2195-2199.
20. Habib A., Creminon C., Frobert Y., Grassi J., Pradelles P., Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J. Biol. Chem. 268:1993;23448-23454.
21. Hawkey C., Kahan A., Steinbruck K., Alegre C., Baumelou E., Begaud B., Dequeker J., Isomaki H., Littlejohn G., Mau J., Papazoglou S. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br. J. Rheumatol. 37:1998;937-945.
22. Hla T., Ristimaki A., Narko K., Ben-Av P., Lee M.J., Evans M., Liu C., Sano H. Role of the early response gene cyclooxygenase (COX)-2 in angiogenesis. Maragoudakis M.E. Molecular, Cellular, and Clinical Aspects of Angiogenesis. 1996;191-198 Plenum, New York.
23. Hsu S.M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29:1981;577-580.
24. Kargman S., Charleson S., Cartwright M., Frank J., Riendeau D., Mancini J., Evans J., O'Neill G. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 111:1996;445-454.
25. Kargman S., Wong E., Greig G.M., Falgueyret J.P., Cromlish W., Ethier D., Yergey J.A., Riendeau D., Evans J.F., Kennedy B., Tagari P., Francis D.A., O'Neill G.P. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem. Pharmacol. 52:1996;1113-1125.
26. Knott I., Dieu M., Burton M., Houbion A., Remacle J., Raes M. Induction of cyclooxygenase by interleukin-1: comparative study between human synovial cells and chondrocytes. J. Rheumatol. 21:1994;462-466.
27. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., Herschman H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266:1991;12866-12872.
28. Langman M.J.S., Weil J., Wainwright P., Lawson D.H., Rawlins M.D., Logan R.F.A., Murph M., Vessey M.P., Colin-Jones D.G. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;1075-1078.
29. Lee S.H., Soyoola E., Chanmugam P., Hart S., Sun W., Zhong H., Liou S., Simmons D., Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macropharges stimulated with lipopolysaccharide. J. Biol. Chem. 267:1992;25934-25938.
30. Lemmel E.M., Bolten W., Burgos Vargas R., Platt P., Nissila M., Sahlberg D., Bjorneboe O., Baumgartner H., Valat J.P., Franchimont P., Bluhmki E., Hanft G., Distel M. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J. Rheumatol. 24:1997;282-290.
31. Lipscomb G.R., Wallis N., Armstrong G., Rees W.D.W. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br. J. Clin. Pharmacol. 46:1998;133-137.
32. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3228-3232.
33. Meade E.A., Smith W.L., DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268:1993;6610-6614.
34. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U. S. A. 90:1994;11693-11697.
35. Ogino K., Hatanaka K., Kawamura M., Katori M., Harada Y. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology. 55:1997;44-53.
36. O'Sullivan M.G., Chilton F.H., Huggins E.M., McCall C.E. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J. Biol. Chem. 267:1992;14547-14550.
37. Pairet M., Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. Vane J., Botting J., Botting R. Improved Non-steroid Anti-Inflammatory Drugs-COX-2 Enzyme Inhibitors. 1996;103-119 Kluwer Academic Publishing, London.
38. Pairet M., Ryn J.V., Schierok H., Mauz A., Trummlitz G., Engelhardt G. Differential inhibition of cyclooxygenase-1 and -2 by meloxicam and its 4′ isomer. Inflammation Res. 47:1998;270-276.
39. Palmer B.F. Renal complications associated with use of nonsteroidal anti-inflammatory agents. J. Invest. Med. 43:1995;516-533.
40. Patrono C., Ciabattoni G., Patrignani P., Pugliese F., Filabozzi P., Catella F., Davi G., Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 72:1985;1177-1184.
41. 2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med. 184:1996;883-891.
42. Rodriguez L.A.G., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;769-772.
43. Rosenberg L., Palmer J.R., Zauber A.G., Warshauer M.E., Stolley P.D., Shapiro S. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst. 83:1991;355-358.
44. Sano H., Forough R., Maier J.A.M., Case J.P., Jackson A., Engleka K., Maciag T., Wilder R.L. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J. Cell Biol. 110:1990;1417-1426.
45. Sano H., Hla T., Maier J.A.M., Crofford L.J., Case J.P., Maciag T., Wilder R.L. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin. Invest. 89:1992;97-108.
46. Schafer A.I. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J. Clin. Pharmacol. 35:1995;209-219.
47. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxigenase-2 in inflammation and pain. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12013-12017.
48. Sheng H., Shao J., Kirkland S.C., Isakson P., Coffey R.J., Morrow J., Beauchamp R.D., DuBois R.N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99:1997;2254-2259.
49. Smalley W.E., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39:1997;1-20.
50. Smith W.L., De Witt D.L. Prostaglandin endoperoxide H synthases-1 and -2. Adv. Immunol. 62:1996;167-215.
51. Szczepanski A., Moatter T., Carley W.W., Gerritsen M.E. Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1. Arthritis Rheum. 37:1994;495-503.
52. Thun M.J., Namboodiri M.M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325:1991;1593-1596.
53. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 231:1971;232-237.
54. Vane J.R., Botting R.M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. 25:1996;9-21.
55. Vane J.R., Mitchell J.A., Appleton I., Tomlinson A., Bishop-Bailey D., Croxtall J., Willoughby D.A. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc. Natl. Acad. Sci. U. S. A. 91:1994;2046-2050.
56. Willard J.E., Lange R.A., Hillis L.D. The use of aspirin in ischemic heart disease. N. Engl. J. Med. 327:1992;175-181.
57. Xie W., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. U. S. A. 88:1991;2692-2696.
58. 2 production. Inflammation Res. 45:1996;246-253.